Acon Pharma
Acon Pharmaceuticals Inc. (Acon Pharma) is a specialty pharmaceutical company and focuses on BLA, ANDA, and 505(b)(2) NDA drug product development with its captive drug delivery system technology platforms. Acon Pharma provides service to its partners and customers to accelerate their IND and NDA product development by out-licencing its captive drug delivery platforms, pre-formulation, formulation, process development, and manufacturing of different types of dosage forms and drug delivery products. Our expertise covers drug development and delivery of poorly soluble small molecule drugs, siRNA, oligonucleotides, peptides, protein, and plasmid DNA. Our formulation technology platforms include nanoparticles, microspheres / microparticles, nanocrystals, liposome, implant, long-acting injectable, oral fast dissolving film (ODF), transdermal patches, resinate / polistirex suspension, nasal spray, topical cream, gel, ointment, nanoemulsion, microemulsion, self-emulsifying system, tablets, capsules, inhalers, controlled release, modified release, and delayed release.
Xudong Yuan
CEOAnGes, Inc.
AnGes is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of gene-based medicines including gene therapy, oligonucleotide drugs and DNA vaccines.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.
Masaki Nakanishi
Director, Business DevelopmentConsulate General of Canada in Shanghai
For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.
Lulu Mi
Life Sciences Trade CommissionerCredevo Pte. Ltd.
Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.
Drive Therapeutics, LLC
Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.
Ryan Quick
Co-founder and COOLibera Bio
Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Olivier Jarry
CEOWanbang Biopharmaceuticals (Group) Co., Ltd
Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).